PSNL · Personalis, Inc.

The thesis

Personalis now trades as a fixed claim on Tempus AI's agreed offer of $16.25 per share. That leaves the shares little room to beat the market. Two things decide it: whether the US antitrust waiting period expires as scheduled on 2 October 2026, and whether a higher offer ever becomes binding.

The shares closed at $16.28 on 30 September 2026, three cents above the deal value. Tempus fixed the value at $16.25 for any Tempus price above $48.42 under the 20 July 2026 merger agreement. Market data showed Tempus shares trading between $81.45 and $86.25 on 30 September 2026, well above that threshold. At these prices, the remaining return to closing is close to zero unless the terms improve.

The narrative is saturated: the sale process has been public since a 17 July 2026 StreetInsider report, and on 15 September 2026 Tempus chief executive Eric Lefkofsky said he did not expect a higher competing bid (Form 425). No amendment to the offer has been disclosed since then.

Bullish and bearish views on Personalis, Inc.

The bull case on Personalis, Inc. (PSNL), in brief: US antitrust clearance is days away. The bear case: The acquirer rules out a richer price.

Bull case

• US antitrust clearance is days away. A merger filing says Tempus refiled its Hart-Scott-Rodino (HSR) premerger notification on 2 September 2026, so the 30-day waiting period expires at 11:59 p.m. Eastern on 2 October 2026. The UK Competition and Markets Authority (CMA) said on 13 August 2026 that it had no further questions.
• Higher interest existed before signing. The 31 August 2026 Form S-4 says a bidder called Party A ultimately proposed $17.00 per share verbally, in stock, before the 20 July 2026 agreement.
• The business was growing at signing. Personalis reported second-quarter clinical volume of 10,384 tests on 4 August 2026, up 199% year over year and 33% from the prior quarter. That supports the standalone value if the deal fails.

Bear case

• The acquirer rules out a richer price. On 15 September 2026 Lefkofsky said he saw no higher bid coming and questioned why Personalis traded above the agreed price (Form 425).
• The contract limits a superior offer. The 31 August 2026 S-4 states that Personalis cannot terminate the agreement to accept a superior proposal. Termination fees of about $76.8 million apply in both directions.
• Analysts sit below the deal price. Ten analysts carry an average target of $14.54 and a consensus Hold rating (four Buy, five Hold, one Sell), according to MarketBeat data published 29 September 2026. Needham cut its rating to Hold on 20 July 2026, and BTIG moved its target to the $16.25 deal value the same day.
• Standalone visibility is thin. Personalis withdrew guidance and stopped quarterly earnings calls on 4 August 2026 because of the pending merger.

Price setup

The shares closed at $16.28 on 30 September 2026, 11.4% below the 52-week high of $18.38. They have gained 19.5% over three months. The 14-day relative strength index (RSI) is 48.4, which is neutral. The price has stayed within cents of $16.25 since mid-September and moves with the deal, not with the business.

Insider selling is small and mechanical. On 18 September 2026 the chief financial officer sold 2,931 shares, the chief legal officer 2,068 shares and the president and chief medical officer 3,998 shares, all at $16.22, according to Form 4 reports. The chief legal officer's filing says the sale covered tax withholding on vested equity; MarketBeat describes the CFO sale the same way. No new share issuance has been disclosed.

Catalysts, next 30 days

• ~5 November 2026, est.: The third-quarter report on Form 10-Q. With calls discontinued, it is the only update on standalone revenue and test volume.

Elapsed catalysts

• 2 October 2026: The HSR waiting period expires at 11:59 p.m. Eastern unless the Federal Trade Commission or the Department of Justice issues a second request. Expiry clears the main US regulatory step. (passed 10d ago)
• Date not yet set: The Personalis stockholder vote. The S-4 filed 31 August 2026 is preliminary, and the meeting date will appear in the definitive proxy. (passed 42d ago)

What would change the view

The low rating would rise with a binding amendment that lifts the consideration above $16.25, or a public superior proposal that Tempus has to match. Neither has been disclosed as of 1 October 2026.

The case for the shares tracking the deal value would break on a second request from US antitrust agencies, a further withdrawal and refiling of the HSR form, or a termination of the agreement. A sustained fall in Tempus's 15-day volume-weighted average price below $48.42 would also reduce the per-share value. Below $46.00, Personalis gains a right to terminate in a two-business-day window before closing. A daily close below $15.50 would show the market pricing real doubt about completion.

What it trades with

While Tempus trades above $48.42, Personalis shares move very little with Tempus, biotech diagnostics or the S&P 500. They behave like a short-dated claim on $16.25. That link reverses only if Tempus falls toward the collar, when Personalis would track Tempus stock at the maximum exchange ratio of 0.3356. If the deal breaks, the shares would reprice on the standalone molecular residual disease (MRD) testing business, without company guidance and with Merck, a holder of more than 10% and a major biopharma customer, as the main counterparty.